Today's Date: September 25, 2023
THE BLACK WOMEN'S AGENDA, INC. HOSTS 46TH ANNUAL SYMPOSIUM TOWN HALL & AWARDS LUNCHEON   •   No more oil, gas and coal. Two nation-states join growing bloc of countries calling for a Fossil Fuel Non-Proliferation Treaty   •   Statement by Minister Khera on Yom Kippur   •   Statement by the Prime Minister on Yom Kippur   •   Student Entrepreneurs from Yale University Win Prestigious $1 Million 2023 Hult Prize   •   Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo   •   Intel Editorial: Intel Addresses Semiconductor Workforce Shortage   •   Shift4 Partners with Give Lively to Offer Powerful Fundraising Solution to Nonprofits   •   Wondershare FamiSafe 7.0 safeguarding Children with AI   •   2023 GLOBAL CITIZEN FESTIVAL SEES $240 MILLION COMMITMENT FROM FRANCE AND NORWAY TO COMBAT THE GLOBAL FOOD CRISIS   •   France Announces €40 Million in New Funding to Education Cannot Wait at Global Citizen Festival   •   Guidewire Optimistic About New Direction of California Insurance   •   Sixth Annual War Heroes on Water Charity Sportfishing Tournament Kicks Off, Bringing Hope and Healing to Combat-Wounded Veterans   •   2023 Gangnam Festival to be Held in Gangnam, the Heart of K-pop   • collaborates with   •   A Meyers Manx Collaboration with Artist Sage Vaughn Contributes $200,000 to Arts Education Fundraiser   •   Joint Statement on the Importance of Comprehensive, Multidisciplinary and Collaborative Care for Patients with Peripheral Artery   •   PRAIRIE VIEW A&M UNIVERSITY ANNOUNCES 2023-2024 WRITER-IN-RESIDENCE ATTICA LOCKE   •   Disappointment and Hope after U.N. General Assembly Wraps, says AHF   •   65+ Populations in Upstate NY's 4 Largest Regions Surging, Getting Poorer; AARP NY to Meet with Local Leaders
Bookmark and Share

VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor, VIC-1911, and G12C Inhibitor, S

BOSTON , June 05 /Businesswire/ - VITRAC Therapeutics, LLC (VITRAC) presented a poster on the Phase 1a/1b clinical trial of aurora kinase A (AURKA) inhibitor, VIC-1911, as monotherapy and in combination with KRAS G12C inhibitor, sotorasib. The study targets the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC). The findings were presented at the prestigious 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 4.

The clinical investigators involved in the study include S. B. Goldberg, MD, MPH, Principal Investigator (PI) and Study Chair at Yale Cancer Center, S. R. Punekar, MD, PI, NYU Langone-Laura and Isaac Perlmutter Cancer Center, V. Velcheti, MD, PI, New York University Perlmutter Cancer Center, J. W. Riess, MD, PI, University of California Davis Comprehensive Cancer Center, K. A. Scilla, MD, PI, University of Maryland Cancer Center, J. W. Carlisle, MD, PI, Emory University Winship Cancer Center, K. Politi, PhD, J.W. Lee, PhD, and B. Burtness, MD, Yale School of Medicine and Yale Cancer Center, T. Myers, MD, and L. Paradiso, DVM, Vitrac Therapeutics.

VIC-1911 is a highly selective, orally administered small molecule inhibitor of AURKA. Overexpression of the AURKA is found in multiple tumors, including NSCLC. New treatment approaches are urgently needed to mitigate and overcome resistance to KRAS G12C inhibitors.

Preclinical studies indicate that AURKA could play a role in resistance to KRAS G12C inhibitors. VIC-1911, both as monotherapy and in combination with a KRAS G12C inhibitors sotorasib and adagrasib, has shown effectiveness against NSCLC with intrinsic and acquired resistance to KRAS G12C inhibitors in preclinical models. These findings suggest the potential of VIC-1911, both as a monotherapy and in combination with sotorasib, for patients with KRASG12C-mutated NSCLC.

"We now have two approved KRAS G12C inhibitors, sotorasib and adagrasib, to treat patients with KRAS G12C-mutated NSCLC," stated Sarah Goldberg, MD, Study Chair. "Despite the satisfactory response rates in patients naïve to KRAS G12C inhibitor therapy, over 50% of patients exhibit primary resistance. Moreover, many patients who do respond soon develop acquired resistance and relapse. With this innovative approach combining AURKA and KRAS G12C inhibitors, we aim to enhance therapeutic outcomes for our patients with KRAS G12C-mutant NSCLC."

"VIC-1911 is a potent, selective AURKA inhibitor. The supporting preclinical studies strongly advocate for the combination of AURKA inhibition with VIC-1911 and KRAS G12C inhibitors in KRAS G12C-mutant NSCLC," said Thomas Myers, MD, Chief Medical Officer at VITRAC. "Through this multi-targeted approach, we hope to deliver more effective therapeutic outcomes for patients with KRAS G12C-mutant NSCLC."

About VITRAC Therapeutics, LLC:

VITRAC Therapeutics is a comprehensive oncology research and development company, excelling in the development, management, and optimization of global pharmaceutical drug development programs, from advanced discovery and translational research to clinical development, market authorization, and post-marketing life-cycle management.

STORY TAGS: Conference, Illinois, Massachusetts, Health, Oncology, Clinical Trials, United States, North America,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News